Why patient engagement must come first in rare disease trials
February 23, 2026 | clinical trials, patient engagement, rare disease
Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients’ lives to build trust and improve outcomes.
For the millions of people living with a rare disease,1 a clinical trial can offer the brightest glimmer of hope. Yet the path to translating clinical trial progress into treatment breakthroughs can be difficult, which can erode trust in these communities. As Rare Disease Day draws near, this month we reflect on a critical truth – successful rare disease trials are not built on scientific ambition alone. They are built on a foundation of genuine patient engagement, designed around the realities of patients’ lives.
The unique challenges of rare disease trials
Developing treatments for rare diseases presents a unique set of obstacles. The patient populations are, by definition, very small and often geographically scattered,2 which makes recruiting enough participants for a study a significant hurdle from the very start.
But there is also a profound human element that needs consideration. Patients and their families carry a heavy emotional burden, navigating diagnoses that few understand. Many face a long, frustrating journey to reach the right diagnosis, often experiencing multiple misdiagnoses and enduring treatments that provide little or no relief, further eroding trust in mainstream healthcare.3,4 Asking them to participate in a trial adds another layer of complexity. The burden of travel to specialist sites, time away from work and/or school and support systems, demanding schedules, and invasive procedures accumulates quickly.5 The strain of participation is more than just a logistical issue; it’s also an emotional and financial one.
Where rare disease trial design can evolve
Patient engagement is especially critical in rare diseases research, yet it is often introduced later in the trial-planning process. This leads to study objectives, designs, and requirements that do not meet the needs of participants. Patients and families are often the true experts in their condition, with deep experiential knowledge that can meaningfully inform trial objectives and goal setting. If participants are brought into the conversation earlier, there is greater opportunity to shape protocols that reflect the realities of living with a rare condition and to enable meaningful, practical input.6
Although regulatory requirements must be met, translating complex scientific information into language that is understandable for non-scientists is particularly important in rare disease communities, where highly knowledgeable patients and caregivers may still face information overload. For example, interviews with people living with idiopathic pulmonary fibrosis revealed that the volume and complexity of information can make clinical trial material difficult to understand.5 Clear communication supports confidence, trust, and informed participation.
Rare disease trials also present a unique opportunity to more fully recognise the crucial role of caregivers. Caregivers are deeply embedded in the patient journey – managing logistics, interpreting information, providing emotional support, and frequently influencing participation decisions. Thoughtfully considering their needs, capacity, and insights can strengthen engagement and improve the overall trial experience for both patients and families.
Designing trials in this context requires careful, practical consideration of how studies are structured, communicated and delivered – not just scientific intent.
What meaningful patient engagement looks like in rare disease trials
True patient engagement starts early and is woven into the very fabric of the trial design. In practice, this often comes down to a small number of critical questions: when and how patients are involved, how participation burden is assessed, how information is shared, and whether caregivers are actively supported as part of the trial journey. While established patient groups provide crucial input, meaningful engagement also requires looking beyond these pools to hear wider perspectives. Actively reaching out to underrepresented communities ensures that these foundational questions are answered in a way that reflects a more complete spectrum of experiences, shaping whether engagement is truly meaningful or merely symbolic.
To support this kind of practical decision-making, we’ve captured these engagement considerations in a short, practical checklist to help teams translate patient-centred principles into trial design decisions.
This mindset prioritises clear, empathetic communication. It means replacing jargon with plain language and ensuring families feel heard and respected throughout the process. It’s about designing for feasibility, not perfection. A slightly less ambitious trial that retains all its participants is far more valuable than a “perfect” one that no one can complete.
Why this matters for trial success
A patient-first approach not only addresses the inherent challenges of rare disease research but also directly impacts trial outcomes. When we put patients first, everyone benefits.7 A trial designed with patient realities in mind is more likely to meet its recruitment goals. Participants who feel understood and supported are far more likely to remain in a study, enabling the collection of high-quality data.
Most importantly, it builds trust. By demonstrating a genuine commitment to the community’s well-being, we forge long-term relationships that extend far beyond a single study. Trust then becomes the bedrock for future research and innovation.
References:
- The Lancet Global Health. The landscape for rare diseases in 2024. Available at: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00056-1/fulltext. Accessed January 2026.
- Boulanger V, et al. Pharmaceut Med. 2020;34(3):185–190.
- Bruce IN, et al. Lupus Science & Medicine. 2023;10:e000856.
- Lupus UK. Research in the news – The impact of misdiagnosis. Available at: https://lupusuk.org.uk/2025/03/03/research-in-the-news-the-impact-of-misdiagnosis/. Accessed February 2026.
- Frost J, et al. Health Expectations. 2025;28: e70260.
- Gaasterland CMW, et al. Orphanet J Rare Dis. 2019;14:31.
- Gobat N, et al. Lancet Glob Health. 2025;13(4):e716–e731.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Cuttsy+Cuttsy are named as one of the Best Places to Work
Campaign Magazine have released its 2022 ranking for the best places to work and Cuttsy+Cuttsy have come in right at the top at No.3.
Promoting trust: Cuttsy+Cuttsy become a PIF Tick accredited agency
Cuttsy+Cuttsy join a host of noteworthy healthcare charities and institutions as one of the first healthcare communications agencies to receive the Patient Information Forum’s seal of approval – the PIF...
Listening to heads AND hearts in healthcare
We talk a lot about using emotions in healthcare communications, but not as much about the business intelligence(BI) behind it. Find out why it matters and why we are proud...
Does being an independent agency really matter?
With Cuttsy+Cuttsy ranked as #6 in the Independent Agencies listing from PM Live’s T40 Creative Healthcare Agencies 2021, Mathew Cutts reflects on what being ‘independent’ means to him.
Opening up about patient engagement
Read the third blog of the series looking at key barriers to effective patient engagement in pharma
Committing time to making meaningful connections – top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma
Key barriers to effective patient engagement in pharma, and how to fix them: Making engagement processes more patient friendly
In the first of this blog series, Patient Engagement Lead, Philippa Pristerà looks at making engagement processes more patient friendly
Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
Healthcare communications agency, Cuttsy+Cuttsy, has been awarded ‘We invest in People, Gold’ from Investors in People.
Cuttsy+Cuttsy marks its 10th anniversary with the launch of Cuttsy Cares
Healthcare communications agency, Cuttsy+Cuttsy, has announced the launch of Cuttsy Cares, in celebration of its 10th anniversary. The agency's charitable programme will deliver up to £10,000 to help improve the quality...
Caroline Benson and Colin Williams to Chair the PM Society from February 2020
For the first time both industry and agencies will be equally represented as the PM Society appoints a joint chair.